Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development.

ABSTRACT: SARS-CoV-2 poses an ongoing threat to human health as variants continue to emerge. Several effective vaccines are available, but a diminishing number of Americans receive the updated vaccines (only 22% received the 2023 update). Public hesitancy towards vaccines and common occurrence of "breakthrough" infections (i.e., infections of vaccinated individuals) highlight the need for alternative methods to reduce viral transmission. SARS-CoV-2 enters cells by fusing its envelope with the target cell membrane in a process mediated by the viral spike protein, S. The S protein operates via a Class I fusion mechanism in which fusion between the viral envelope and host cell membrane is mediated by structural rearrangements of the S trimer. We previously reported lipopeptides derived from the

SUBMITTER: Kuhn AJ 

PROVIDER: S-EPMC11915835 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature